Mesa Laboratories Insider Sells 125 Shares

On June 18, 2026, Crennen Lyndsey Elizabeth, Chief Accounting Officer of Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 125 shares of the company's stock. The transaction occurred at an unspecified price, but the stock traded around $93.23 on Tuesday.

What Changed in Crennen Lyndsey Elizabeth's Mesa Laboratories Position

Crennen Lyndsey Elizabeth reduced her holdings in Mesa Laboratories by selling 125 shares. The specifics of the transaction price were not disclosed, and the sale was not planned under Rule 10b5-1.

Other Institutional Activity in Mesa Laboratories

Long Path Partners LP significantly increased its stake in Mesa Laboratories, adding 178,360 shares for a total of 405,583 shares valued at approximately $35.9 million. BlackRock, Inc. slightly trimmed its position by 4,815 shares, holding 393,851 shares worth about $34.8 million. Boston Partners boosted its holdings by 55,335 shares, ending with 268,711 shares valued at $23.8 million. Select Equity Group, L.P. increased its stake by 29,450 shares, bringing its total to 235,885 shares worth roughly $20.9 million. Vanguard Capital Management LLC opened a new position with 232,643 shares valued at $20.6 million.

Mesa Laboratories, Inc. Stock Down 27.7%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company has a market capitalization of approximately $515.1 million and a P/E ratio of 77.05, with a forward P/E of 7.60. Its beta is 0.927, indicating less volatility than the market. The stock's 52-week range is between $55.45 and $113.99, with a 50-day moving average of $101.99 and a 200-day moving average of $84.97. Mesa Laboratories maintains a current ratio of 1.717 and a quick ratio of 1.174, with a debt-to-equity ratio of 90.65.

Recent Earnings

Mesa Laboratories reported revenue of $249.13 million, showing a growth rate of 2.6%. The company's net margin stands at 2.69%, with a return on equity of 3.88%. Earnings per share were $1.21. The next earnings report is expected on August 5, 2026.

Dividend

The company pays an annual dividend of $0.64 per share, yielding 0.67%. Its dividend payout ratio is 52.89%.

Insider Buying and Selling at Mesa Laboratories, Inc.

On June 22, 2026, Crennen Lyndsey Elizabeth sold 442 shares at $89.50, while Brian David Archbold, Senior Vice President of Operations, sold 2,516 shares at the same price. John Sakys, Chief Financial Officer, sold 2,827 shares on the same day. Earlier, on June 18, 2026, John Sakys purchased 2,282 shares at $95.10, and Brian David Archbold bought 1,859 shares at the same price.

Analysts Set New Price Targets

On February 4, 2026, Wells Fargo maintained a "hold" rating for Mesa Laboratories with a price target of $94. The consensus among analysts is a "hold" rating, with a mean price target of $112 based on two analyst opinions.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, develops and manufactures life sciences tools and quality control products. Serving markets across North America, Europe, and the Asia Pacific, the company operates through segments including Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Mesa Labs provides testing services for pharmaceutical and healthcare industries and offers products like MassARRAY genetic analysis tools and Gyrolab systems for protein analysis.

Bottom Line

Mesa Laboratories, Inc. is under the spotlight following insider sales by its CAO. Investors often track such moves to gauge insider sentiment. It's important to remember that 13F filings and insider transactions reflect past actions and may not necessarily indicate current positions or future performance.